Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback